These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 163929)

  • 1. Correlation of pre-treatment serum 17-hydroxycorticosteroid values with survival in patients with prostatic cancer.
    Blackard CE; Byar DP; Seal US; Doe RP
    J Urol; 1975 Apr; 113(4):517-20. PubMed ID: 163929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of pretreatment serum nonprotein-bound cortisol and total 17-hydroxycorticosteroid values with survival in patients with prostatic cancer.
    Blackard CE; Byar DP; Seal US; Doe RP
    N Engl J Med; 1974 Oct; 291(15):751-5. PubMed ID: 4369891
    [No Abstract]   [Full Text] [Related]  

  • 3. [Serum levels of phosphatases after hormonal stimulation in the early diagnosis of prostatic cancer].
    Tamborini G; Lojacono L; Ronzoni G; Alcini E; Landi E
    Chir Patol Sper; 1967; 15(2):239-44. PubMed ID: 4179630
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of total and prostatic fraction serum acid phosphatase levels in patients with differentiated and undifferentiated prostatic carcinoma.
    Murphy GP; Reynoso G; Kenny GM; Gaeta JF
    Cancer; 1969 Jun; 23(6):1309-14. PubMed ID: 4306102
    [No Abstract]   [Full Text] [Related]  

  • 5. [Evaluation of the behavior of serum phosphatases in prostatic neoplasms].
    Alcini E; Ronzoni G; Wiel Marin A
    Chir Patol Sper; 1967; 15(2):288-95. PubMed ID: 4178181
    [No Abstract]   [Full Text] [Related]  

  • 6. Biologic and pathophysiologic prognosticating indices in prostatic cancer.
    Madduri SD; Sporer A; Seebode JJ
    Am Surg; 1978 May; 44(5):290-5. PubMed ID: 666117
    [No Abstract]   [Full Text] [Related]  

  • 7. [Enzyme activities and bone metastasizing in prostatic carcinoma].
    Münchow H; Lohse R
    Dtsch Gesundheitsw; 1972 Jun; 27(26):1220-3. PubMed ID: 4342570
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma corticotropin (ACTH), growth hormone (GH), and 11-OHCS (hydroxycorticosteroid) response during surgery.
    Ichikawa Y; Kawagoe M; Nishikai M; Yoshida K; Homma M
    J Lab Clin Med; 1971 Dec; 78(6):882-90. PubMed ID: 4331974
    [No Abstract]   [Full Text] [Related]  

  • 9. Outcome evaluation of the 1997 American Joint Committee on Cancer staging system for prostate carcinoma treated by radiation therapy.
    Iyer RV; Hanlon AL; Pinover WH; Hanks GE
    Cancer; 1999 Apr; 85(8):1816-21. PubMed ID: 10223577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnostic and prognostic value of serum phosphatases and PSA (prostate-specific antigen) in prostatic carcinoma].
    Sohn M; Studer UE
    Schweiz Rundsch Med Prax; 1988 May; 77(20):551-5. PubMed ID: 2455317
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
    Stege R; Grande M; Carlström K; Tribukait B; Pousette A
    Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aldolase, acid phosphatase and prostatic phosphatase in the blood of patients with prostatic cancer].
    Pandov Kh; Dimitrova S; Ivanova Ts; Khadzhistoikov P
    Vutr Boles; 1971; 10(6):76-80. PubMed ID: 4346429
    [No Abstract]   [Full Text] [Related]  

  • 13. [Current status of diagnosis and stage classification of prostatic carcinoma].
    Harzmann R; Bichler KH
    Med Klin; 1977 Oct; 72(40):1649-54. PubMed ID: 199828
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic value of urokinase plasminogen activator for prostatic carcinoma.
    Lehmann K; Plas E; Gautschi K; Hauri D
    Urol Int; 1994; 52(3):159-61. PubMed ID: 7515534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Behavior of serum phosphates in prostatic neoplasms after hormonal stimulation. (Experimental study)].
    Ronzoni G; Lojacono L; Alcini E; Landi E; Tamborini G
    Chir Patol Sper; 1967; 15(2):203-15. PubMed ID: 4302590
    [No Abstract]   [Full Text] [Related]  

  • 16. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.
    Zietman AL; Coen JJ; Shipley WU; Willett CG; Efird JT
    J Urol; 1994 Mar; 151(3):640-5. PubMed ID: 7508522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis of bone metastasis of prostatic carcinoma with strontium 87m and Anger camera].
    Aberle B; Höfer R; Willvonseder R
    Helv Chir Acta; 1970 Aug; 37(4):534-7. PubMed ID: 4325798
    [No Abstract]   [Full Text] [Related]  

  • 18. Studies on circadian periodicity of plasma 17-hydroxycorticosteroids (17-OHCS) in carcinoma of the breast.
    Singh RK; Mahdi AA; Singh D; Rai SP; Cornélissen G
    In Vivo; 1995; 9(4):279-82. PubMed ID: 8555426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circadian variation of plasma 17-hydroxycorticosteroid (17-OHCS) in cavitary and non-cavitary pulmonary tuberculosis.
    Singh S; Singh SK; Singh S; Singh RC; Sharma MK
    Indian J Physiol Pharmacol; 1991 Oct; 35(4):286-8. PubMed ID: 1812110
    [No Abstract]   [Full Text] [Related]  

  • 20. Estracyt (NSC 89199) as a substrate for phosphatases in human serum.
    Tritsch GL; Shukla SK; Mittelman A; Murphy GP
    Invest Urol; 1974 Jul; 12(1):38-9. PubMed ID: 4366126
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.